Impact of Anti-TNF α Treatment on Persistent Non-Infectious Uveitis in Children in Saudi Arabia
-
By
-
Abeer Aljahdali
-
Abrar A. Alhawsawi
-
Maram Alenazi
-
Moustafa S. Magliyah
-
Hassan Al-Dhibi
-
January 17, 2026
-
Clinical Scorecard: Impact of Anti-TNF α Treatment on Persistent Non-Infectious Uveitis in Children in Saudi Arabia
At a Glance
| Category | Detail |
|---|
| Condition | Persistent Non-Infectious Uveitis in Children |
| Key Mechanisms | Anti-TNF-α therapies reduce inflammation and complications associated with uveitis. |
| Target Population | Children diagnosed with refractory non-infectious uveitis. |
| Care Setting | Tertiary eye hospital in Saudi Arabia. |
Key Highlights
- Pediatric uveitis accounts for less than 10% of all uveitis cases but has a high risk of complications.
- Anti-TNF-α medications like Infliximab and Adalimumab are effective in treating refractory cases.
- The study included 32 patients with a mean follow-up duration of 7.6 years.
Guideline-Based Recommendations
Diagnosis
- Use the Standardization of Uveitis Nomenclature (SUN) Classification Scale for diagnosis.
Management
- Initiate treatment with anti-TNF-α medications for refractory cases not responsive to conventional immunosuppressants.
Monitoring & Follow-up
- Regular follow-ups to assess best corrected visual acuity (BCVA) and inflammatory activity.
Risks
- Monitor for potential complications from prolonged corticosteroid use.
Patient & Prescribing Data
Children aged ≤ 18 years with refractory non-infectious uveitis.
Anti-TNF-α therapies have shown significant improvements in managing chronic uveitis.
Clinical Best Practices
- Conduct a thorough uveitis workup to determine the cause and type of uveitis.
- Utilize multimodal imaging for assessment and monitoring of ocular complications.
- Ensure compliance with prescribed medications and monitor for side effects.
References
